ProMIS Neurosciences (PMN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Key milestones and financial position

• Completed enrollment of 144 patients in a robust, oversubscribed phase 1b Alzheimer's study in December, with monthly dosing over 12 months and three ascending doses.

• Secured up to $175 million in oversubscribed financing from top-tier investors, ensuring full funding through upcoming data readouts.

• Interim qualitative analysis of trial data expected mid-year, with final top-line results anticipated by year-end.

• Study design aims to provide a definitive answer on efficacy and safety, focusing on early Alzheimer's patients with mild cognitive impairment.

• High patient retention and investigator enthusiasm attributed to the potential for reduced ARIA risk and differentiated safety profile.

Scientific platform and differentiation

• Proprietary EpiSelect platform enables design of highly selective antibodies targeting toxic oligomers, believed to drive cognitive decline in Alzheimer's.

• PMN310 is the only antibody in development shown not to bind plaque or monomers, reducing off-target effects and ARIA risk.

• Preclinical studies demonstrated strong efficacy and safety, with no treatment-related serious adverse events observed to date in the clinical trial.

• Platform supports a pipeline targeting other neurodegenerative diseases, including ALS and Parkinson's.

• Proof of concept in Alzheimer's would validate the broader platform and pipeline candidates.

Clinical trial design and endpoints

• Phase 1b study is placebo-controlled, double-blind, and randomized, enrolling a homogeneous early Alzheimer's population.

• Endpoints include a comprehensive biomarker panel, safety (especially ARIA), and clinical outcomes using FDA-approved measures like CDR sum of boxes and ADAS-Cog.

• ARIA rates are expected to be similar to placebo (9–14%), a significant improvement over current market drugs.

• Interim analysis will focus on qualitative trends in biomarker movement and safety, with quantitative efficacy data to be assessed at study completion.

• Biomarker reductions, especially in p-tau217, are anticipated to be at least as strong as those seen with competing therapies.